Search
Viridian Therapeutics Inc
VRDNAdd to Watchlist
17.320USD
+0.040+0.23%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
1.77BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-24The current earnings forecast score of Viridian Therapeutics Inc is 8.59, ranking 98 out of 388 in the Biotechnology & Medical Research industry. The average price target is 40.50, with a high of 50.00 and a low of 19.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
32.867
Target Price
+97.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Viridian Therapeutics Inc
VRDN
17
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Viridian Therapeutics Inc's expected revenue for the next quarter?
Viridian Therapeutics Inc's expected revenue is 13.64K.
What is Viridian Therapeutics Inc's price target?
Analysts forecast that Viridian Therapeutics Inc's price target is USD 40.50, with the highest forecast at USD 50.00 and the lowest forecast at USD 19.00.
How have Viridian Therapeutics IncVRDN's recent earnings per share performed?
The market expectation was USD -1.03, while Viridian Therapeutics IncVRDN's earnings per share (EPS) for the previous quarter was USD -1.27. EPS for the next quarter is expected at USD -1.05.
What is the analyst rating for Viridian Therapeutics Inc?
Based on the ratings of Viridian Therapeutics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
